GlassScriptPhysician profile
Paul J Vana
NPI 1770685075
$11,617.49
in general payments reported to CMS, 2019-2025
49 companies · $6,551 in 2025
The $6,551 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $399 · 2021: $662 · 2022: $1,062 · 2023: $568 · 2024: $1,248 · 2025: $6,551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,545 · Food and Beverage: $1,823.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,544.77 |
| Food and Beverage | $1,822.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,558.54 | 2024-2025 | |
| Abbvie INC. | $718.42 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $678.65 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $542.01 | 2019-2025 | |
| Amgen INC. | $391.19 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $370.75 | 2019-2025 | Bevespi Aerosphere |
| Lilly USA, LLC | $344.97 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.33 | 2019-2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.91 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $151.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.71 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $113.85 | 2019-2022 | |
| Abbott Laboratories | $113.56 | 2019-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $87.48 | 2023 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $84.79 | 2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Vana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.